A rapidly growing biotechnology company that is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology. Our partner is committed to developing a differentiated class of therapeutics for oncology indications and more.

This influential hire provided guidance to programs across the portfolio aimed at developing several highly novel peptide therapeutics. They helped drive programs through IND-enabling studies into clinical development and beyond by integrating science, medicine, and business considerations. They also collaborated with Finance to help track and forecast spending for programs.